Bill, Parliament of Canada, Federal
C-265An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)
C-265, Parliament of Canada: In committee in the House of Commons, last recorded June 10, 2026. Clarion's outlook: unlikely to pass.
Who lobbies on this subject
Organizations with lobbying reports on Agriculture & Food since November 2025, most reports first. This is the bill's policy area, not the bill: activity on the subject, not a position on the bill.8 of 486 organizations shown.
158 reports, most recent August 26, 2026
Canadian Canola Growers Association
143 reports, most recent September 24, 2026
131 reports, most recent August 28, 2026
130 reports, most recent September 24, 2026
Canadian Federation of Independent Business
107 reports, most recent August 27, 2026
Fruit & Vegetable Growers of Canada
102 reports, most recent October 7, 2026
Canadian Agri-food Automation and Intelligence Network (CAAIN)
102 reports, most recent August 31, 2026
The Professional Institute for the Public Service of Canada
92 reports, most recent August 20, 2026
Where it stands
- Status
- In committee in the House of Commons
- Sponsor
- Marcus Powlowski
- Introduced
- Session
- 45-1
Policy areas
- Agriculture & Food · keyword match
What it does
A plain-language summary of the official text, written by AI.
Bill C-265 is a Private Member's Bill introduced in the 45th Parliament that would amend the Food and Drugs Act to establish a list of therapeutic products pre-approved for special access. The bill passed second reading in the House of Commons in June 2026 and is currently under consideration by a House committee. The special access program generally allows patients to obtain drugs or medical devices not otherwise available in Canada, and this bill appears aimed at streamlining that process through pre-approved product listings.
Chances of passing
Worked out from the bill's type, its stage and the government's verified standing; for a federal bill, its passage range sets the band. It is not a guarantee.
Unlikely to pass because it's a private member's bill (which rarely passes) and it's at committee.
Historically 25–40% of comparable federal bills became law (base rate 32%).
If this private member's bill would create new spending, it needs a Royal Recommendation, which only Cabinet can give. Without one, it will almost certainly not pass.
A private member's bill depends on its place in the Order of Precedence, set by a random draw, and bills low on the list often run out of time.
Stages so far
Second reading, House
First reading, House
Follow C-265 and bills like it.
Describe what you care about in a plain sentence, and Clarion finds what matches and ranks it.